Exobiosphere S.à r.l. and Space Cargo Unlimited today announced the signing of a Memorandum of Understanding (MoU) during the Paris Air Show to launch joint space missions focused on high-throughput...

The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new...

Regeneron Pharmaceuticals, Inc. and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting...

Mezzion Pharma Co., Ltd. (Mezzion), a leader in rare disease therapeutics, announced the expansion of its udenafil pipeline with the initiation of a pre-clinical study for Autosomal Dominant...

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it...

Samsung Biologics a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug...

Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in...

iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular...

Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™...

Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced an...

Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials.

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen)  for...